Marijuana companies are gearing up for IPOs — and NYSE and Nasdaq are jonesing to list them

US marijuana firms are accelerating IPO/listing plans as federal barriers ease: a Trump executive order (moved cannabis to Schedule 3) and subsequent DOJ/DEA codification enable DEA-registered medical cannabis companies to access capital markets. The NYSE and Nasdaq are now competing to list these “Pot Inc.” issuers—Glass House Brands listed on the NYSE on June 30, while earlier NYSE listings included Trulieve after exchange bidding. With the industry projected to nearly $100B annually by 2030 and potential further rescheduling toward Schedule IV/V, listing activity could broaden institutional liquidity and investor base despite ongoing exchange fee/cost jockeying.

Analysis

The economic prize here is less about one or two cannabis listings and more about who controls the gate when a previously shut-off sector needs capital. For exchanges, the direct fee pool is trivial, but the strategic value is high: winning an early compliant listing can anchor future mandates with bankers, lawyers, and SPAC/IPO sponsors if the regulatory path keeps opening. That said, if NYSE and Nasdaq both compete on speed and price, this quickly becomes a margin-clearing exercise for the exchanges themselves, not a durable earnings lever.

For plant-touching operators like GLASF, the first-order win is cheaper and broader access to capital; the second-order risk is faster industry crowding. Easier financing tends to lower the cost of entry for weaker operators, which usually compresses gross margin before it improves valuation multiples. The real catalyst path is 1-3 months of proof that banks, auditors, and institutions will actually transact; without that, the move is mostly narrative and secondary issuance could absorb the upside.

Contrarian view: the market may be conflating rescheduling with full legalization. Even a friendlier schedule does not automatically remove tax drag, interstate frictions, or custody constraints, so the rerating may be more gradual than the headline implies. Over 6-18 months, the more durable beneficiaries may be exchanges and ancillary infrastructure, while growers remain exposed to margin pressure and dilution.

Key Decisions for Investors

• Small tactical long GLASF on pullbacks, sized as a regulatory-optionalty trade; target 3-6 months, with a hard stop if DEA/DOJ implementation stalls or management uses the window for a dilutive raise.
• Do not chase NDAQ on the headline alone; the listing-fee impact is immaterial. Only add NDAQ on evidence of a broader high-profile issuance pipeline, where the real upside is signal value and future mandate capture, not this one sector.
• Watch-list, not buy-list, for the broader cannabis complex until banks and institutions show actual custody/clearing access. If that confirmation comes, rotate into ancillary beneficiaries before growers, because margin compression usually lags the first wave of capital access.